BLLN — BillionToOne, Inc.
$114.07+2.34%
Last close: · regular session
Last 60 sessions
BLLN closed at $114.07 (+2.34%) on Oct 27, 2026. Float: 24.4M shares. Latest SEC filing: 144 on Oct 28, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for BLLN in the TickerWise workspace.
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.
Company profile
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: US
- Exchange: NASDAQ
- Employees: 620
- Website: https://www.billiontoone.com
Latest SEC filings for BLLN
Latest BLLN news
- BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026 Read article
- BillionToOne: A Molecular Diagnostics Stock With Strong Quality And GARP Credentials Read article
- BillionToOne's Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.